Clinical Trials | January 24, 2022
RaphaCure partners with Madhavbaug for cardiac healthcare services
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
Madhavbaug has a pan-India presence with a vast network of 272 clinics and two hospitals
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Avra Labs is a Hyderabad based contract manufacturing and research services (CRAMs) and specialty active pharmaceutical ingredients (API) manufacturer with four facilities across the states of Telangana and Andhra Pradesh
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
The country is sixth among the most affected countries by active cases
Go-ahead for pivotal clinical trial which is expected to commence by March
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
UCB plans to submit regulatory applications in Q3 2022
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
Subscribe To Our Newsletter & Stay Updated
